The European CAR‐T map—Current status and future directions to improve access to CAR T‐cell therapy for hematologic malignanciesElise R. A. Pennings, Marie José Kersten, Solène Clavreul et al.|HemaSphere|2026Cited by 2
Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in EuropeDelphine Ammar, Jacquelyn Awigena-Cook, Carmen Sanges et al.|Cytotherapy|2025Cited by 0
Bridging affordability and sustainability of health innovations via novel pricing, cost-effectiveness, and reimbursement models to improve patient access: The ASCERTAIN projectCarin A. Uyl-de Groot, Eline Aas, N Xander et al.|Health Policy and Technology|2026Cited by 0
Bridging affordability and sustainability of health innovations via novel pricing, cost-effectiveness, and reimbursement models to improve patient access: the ASCERTAIN projectCarin A. Uyl-de Groot, Eline Aas, N Xander et al.|London School of Economics and Political Science Research Online (London School of Economics and Political Science)|2026Cited by 0
Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The NetherlandsYansi Wu, Gauthier Quinonez, Maureen Rutten-van Mölken et al.|OSF Preprints (OSF Preprints)|2026Cited by 0